pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Pulmonology · news · pharmadog
← back to Pulmonology
News · Pulmonology
723
stories
23d
Boehringer, Microsoft team up to explore digital patient twins for clinical trials
fiercebiotech
23d
Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial
biospace
23d
BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD cases
fiercebiotech
24d
#ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial
endpoints
24d
#ESMO26: AstraZeneca's Tagrisso-Orpathys combo may extend Tagrisso's life in lung cancer
endpoints
24d
ESMO: BMS’ Massacesi hails ‘very promising’ data for BioNTech-partnered PD-L1xVEGF-A drug
fiercebiotech
24d
#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
endpoints
25d
STAT+: The ESMO presentation everyone’s been waiting for
stat
25d
#ESMO26: Amgen's Imdelltra regimen more than halves risk of death in Phase 3 lung cancer trial
endpoints
25d
ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
fiercebiotech
26d
‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
fiercebiotech
26d
ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3
biospace
26d
ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2
biospace
26d
Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
biospace
26d
How a targeted drug kept one patient alive 15 years — but failed to save her friends
stat
27d
Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra
fiercebiotech
27d
ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak
biospace
27d
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
biopharma dive
27d
Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset
biospace
27d
Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease
biospace
27d
ESMO: Boehringer builds case for late-phase rival to Amgen’s Imdelltra
fiercebiotech
28d
Roche’s CEO has ‘absolutely not’ changed tune on Poseida despite scrapping CAR-T from the buyout
fiercebiotech
28d
ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP says
biospace
28d
ESMO: GSK cancer R&D chief says mo-rez data ‘reinforces our belief’ in ADC as phase 3 push ramps up
fiercebiotech
28d
Roivant, continuing ascent, claims another victory for rare disease drug
biopharma dive
29d
The 6 biggest crossover rounds in biopharma history
biospace
29d
FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women
fda press
29d
Most new drugs are still too costly at launch, ICER says
biopharma dive
29d
‘A two-way conversation with the tumor’: Researchers use ‘avatar’ to predict immunotherapy responses
fiercebiotech
29d
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
biopharma dive
← prev
page 5 of 25
next →